Open AccessManagement of immune checkpoint inhibitor‐related adverse events: A review of case reports
Author(s) -
Si Xiaoyan,
Song Peng,
Ni Jun,
Di Mingyi,
He Chunxia,
Zhang Li,
Liu Xiaowei,
Li Yue,
Wang Hanping,
Guo Xiaoxiao,
Zhou Jiaxin,
Duan Lian,
Yang Xu,
Wang Mengzhao,
Zhang Li
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13315
Subject(s) - durvalumab , tremelimumab , medicine , nivolumab , pembrolizumab , avelumab , atezolizumab , ipilimumab , adverse effect , oncology , clinical trial , intensive care medicine , immunotherapy , cancer
Immune checkpoint inhibitors represent a major breakthrough in cancer therapy. Immune‐related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Management of irAEs is based on clinical experience because it is not easy to conduct prospective trials to evaluate the best treatment strategy. Using a combination of search terms in the PubMed and Embase databases, we reviewed all cases in the English language citing toxicities associated with either pembrolizumab, nivolumab, ipilimumab, atezolizumab, tremelimumab, durvalumab, avelumab or any combination of these agents published before 20 May 2019. A total of 128 reports with 239 cases were included in the study. Here, we summarize the spectrum of toxicities, safety in special patients, rechallenging after irAEs and agents used for treatment of irAEs in those reports.